ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Levetiracetam

Also written as “Levetiracetam (Keppra)”, “levetiracetam” and “Levetiracetam 250 mg”.

Its studies are mostly in Epilepsy · Epilepsies, Partial · Seizures · Cognitive Dysfunction · Epilepsy, Generalized, led by 8 companies.

Drug pageLevetiracetam: every studyMany companies study it; this page follows only the 72 they lead. All 204 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 8, 200572 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCBits history only570 open or runningphase 4since Sep 8, 2005Mar 3, 2005none ahead
Hikma Pharmaceuticalsits history only40 open or runningno phasesince Jan 15, 2009Jan 15, 2009none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Feb 20, 2009Feb 20, 2009none ahead
AgeneBioits history only20 open or runningphase 3since Mar 28, 2018Mar 28, 2018none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since May 26, 2010May 26, 2010none ahead
Ache Laboratorios Farmaceuticosits history only10 open or runningphase 3since Jul 6, 2011Jul 6, 2011none ahead
Desitin Arzneimittelits history only10 open or runningphase 1since Dec 1, 2025Dec 1, 2025none ahead
Novartisits history only10 open or runningphase 1since Jul 24, 2009Jul 24, 2009none ahead

Also a collaborator on its studies: PRA Health Sciences and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Dr. Reddy's Laboratories only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 26, 2010First studies: 2 phase 1 studies in HealthyFirst studyNCT01132352, NCT01131897

TargetBeta

“Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker”ChEMBL 37, by rule

Studies

All 2 Dr. Reddy's Laboratories leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01132352Healthy · United States1CompletedOct 200324
NCT01131897Healthy · United States1CompletedSep 200324

How it is read

Names in the registry

  • “Levetiracetam”, 52 entries
  • “Levetiracetam (Keppra)”, 4 entries
  • “levetiracetam”, 3 entries
  • “Levetiracetam 250 mg”, 3 entries
  • “Levetiracetam 500 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.